Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

PROPOSED CANCELLATION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

On 17 March 2026, in light of the changes in regulatory requirements concerning mandatory provisions for PRC issuers listed overseas, the board (the "**Board**") of directors (the "**Director(s)**") of the Company proposed a special resolution to amend the existing articles of association of the Company (the "**Articles of Association**") to the shareholders of the Company (the "**Shareholder(s)**") for approval at the forthcoming annual general meeting of the Company (the "**2025 AGM**").

The proposed amendments to the existing Articles of Association (the "**Proposed Amendments**") mainly relate to the cancellation of the Supervisory Committee in accordance with the relevant provisions of the Company Law of the People's Republic of China (the "**Company Law**"), with its powers shall be exercised by the Audit Committee of the Board accordingly. Meanwhile, the Articles of Association will be updated accordingly in accordance with the latest regulatory requirements under the Company Law and other relevant laws and regulations, and with reference to the relevant provisions on corporate governance set forth in the Guidelines for Articles of Association of Listed Companies. Full version of the Proposed Amendments will be set out in the circular. The Board is of the view that the Proposed Amendments are in the interests of the Company and the Shareholders as a whole. Before the Proposed Amendments being considered and approved by the Shareholders, the Supervisory Committee will continue to perform its duties in strict accordance with the provisions of relevant laws and regulations and the Articles of Association to safeguard the interests of the Company and the Shareholders.

The Proposed Amendments are subject to the approval of the Shareholders by way of special resolution at the 2025 AGM and, if approved, will become effective upon such approval. Prior to the passing of the relevant special resolution at the 2025 AGM, the existing Articles of Association shall remain valid.

After the Proposed Amendments come into effect, the full text of the revised Articles of Association will be published on the Company's website (http://www.zyloxtb.com) and the Stock Exchange's website (www.hkexnews.hk).

A circular containing, among other things, the full version of the Proposed Amendments together with the notice of the 2025 AGM will be published on the Company's website (http://www.zyloxtb.com) and the Stock Exchange's website (www.hkexnews.hk) in due course.

By Order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, 17 March 2026

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.